IDA HIVAIDS Group Bianca Kamps Director

1
IDA HIV/AIDS GroupBianca Kamps - Director

• Succesful procurement experiences lessons
  learned

August 16th, 2006
2
Joining forces
Jan 1st 2004 IDA HIV/AIDS Group was established,
as a 100 IDA Foundation not-for-profit
affiliate, to create focus on providing
high-quality essential ARVs and medical supplies
at the lowest possible price to LDCs MDCs.
3
131,500 patients served YTD
Based upon quantities of most common first line
treatment EFV, NVP, 3TCd4TNVP, 3TCZDVNVP
4
A dynamic market
June 05 9 generic ARVs WHO-prequalified August
06 27 generic ARVs US-FDA tentative approved
and/or WHO-prequalified
5
IDA HIV/AIDS GROUP UKRAINE
6
Challenges

• Conflicting requirements country registration vs
  GF procurement guidelines
• Drugs took a long time to be delivered
• Eastern Europe is a new challenging area e.g.
  paperwork requirements
• Harsh transport conditions

7
Lessons learned

• Clarity on requirements essential gt Checklist
  developed to ensure they are clear and known
• Management of expectations gt Order process on
  paper that indicates realistic timelines
• Communication between suppliers, procurement
  agent, PR and NAC key gt weekly updates regular
  visits stakeholders
• Quality Assurance for generic ARVs gt from
  manufacturer selection to batch control

8
IDA HIV/AIDS GROUP CÔTE D'IVOIRE
9
Challenges

• Misunderstanding about in-country requirements
  resulted in controlled recall of drugs
• Patent clarification took time, and requires
  update for every delivery
• Mumbai floods caused delays in 2005 generic drug
  deliveries
• Emergency request delayed due to confusion
  amongst stakeholderscausing an almost stock-out
  situation

10
Lessons learned

• Understanding recipient requirements gt Specialist
  team required that is up-to-date with the latest
  status
• Patent issues take time gt Development standard
  patent guidelines to create clarity
• Events in other part of the world resulting in
  emergency situation in recipient country gt
  Anticipate the unexpected
• Communication key in difficult environment gt
  Strong and longstanding relations essential

11
Focus on prevention, treatment care

• Harmonization of guidelines, between donors
  (inter)national registration bodies
• Attention for HIV/TB co-infection and treatment
• Demands for special groups e.g. IDU MSM
• Availability Pediatrics
  wide range of OI-drugs

12
More information

• Please contact us via
• Tel    [phone]
• Fax [phone]
• E mail info_at_idahivaidgroup.org

13
Back up Slides
14
Increasing demand
15
ARV supplies to 47 countries YTD
16
Cornerstones
17
Guaranteed Quality
18
Generic vs branded ARVs
19
Background Ukraine

• 2004 the GFATM requested The Alliance to take
  over the Ukraine program. Need to expand ART
  treatment from lt 60 to 4000 patients within 2
  years.
• ARVs supplied for treatment of 2000 patients in
  04/05, total worth US 4.3 Mio. In 2006 IDA
  HIV/AIDS Group again chosen to provide ARVs
  OIs.
• The Global Funds 2005 annual report highlights
  the exceeding of key targets for roll-out of
  treatment and prevention services.

20
Background Côte dIvoire

• Massive displacement of local populations.
• In 2004 the Supreme Council for HIV/AIDS
  Control, presided over by the Head of State, was
  established.
• UNDP appointed PR for Global Fund Round 2. From
  2004/06 IDA supplied US 4.5 Mio worth of drugs.
• Total number of patients receiving treatment via
  GF is 8000. Target 2006-2008 15,000 patients on
  treatment.